Journal article
Rivaroxaban in Orthopedic Surgery — A Change of Paradigm?
Abstract
Two selective, orally available anticoagulant agents, although with different targets in the coagulation cascade, have recently been approved in many countries on the indication of prophylaxis against venous thromboembolism (VTE) after major joint arthroplasty. This review discusses mainly the antifactor Xa drug, rivaroxaban, with a focus on the orthopedic trials. Pharmacokinetic characteristics and other clinical development programs with …
Authors
Schulman S
Journal
Clinical and Applied Thrombosis/Hemostasis, Vol. 15, No. 6, pp. 613–620
Publisher
SAGE Publications
Publication Date
December 2009
DOI
10.1177/1076029609342094
ISSN
1076-0296